You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Rosuvastatin calcium
Rosuvastatin calcium is a potent HMG-CoA reductase inhibitor (IC50 = 5.4 nM). Inhibits cholesterol synthesis in rat hepatocytes in vitro and in vivo. Reduces plasma LDL cholesterol levels. Enhances lentiviral transduction of natural killer cells. Orally bioavailable.
Compound Libraries for Rosuvastatin calcium
Technical Data for Rosuvastatin calcium
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Rosuvastatin calcium
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Rosuvastatin calcium
The following data is based on the product molecular weight 500.57. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2 mL||9.99 mL||19.98 mL|
|5 mM||0.4 mL||2 mL||4 mL|
|10 mM||0.2 mL||1 mL||2 mL|
|50 mM||0.04 mL||0.2 mL||0.4 mL|
Product Datasheets for Rosuvastatin calcium
References for Rosuvastatin calcium
References are publications that support the biological activity of the product.
McTaggart et al (2001) Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am.J.Cardiol. 87 28B PMID: 11256847
Gong et al (2020) Rosuvastatin enhances VSV-G lentiviral transduction of NK cells via upregulation of the low-density lipoprotein receptor. Mol.Ther.Methods Clin.Dev. 17 634 PMID: 32300610
If you know of a relevant reference for Rosuvastatin calcium, please let us know.
View Related Products by Product Action
Keywords: Rosuvastatin calcium, Rosuvastatin calcium supplier, ZD4522, HMG, CoA, reductase, inhibitors, inhibits, statins, 3-hydroxy-3-methyl-glutaryl-CoA, orally, bioavailable, viral, transduction, enhancers, enhances, HMG-CoA, Reductase, Viral, Transduction, Enhancers, 6343, Tocris Bioscience
1 Citation for Rosuvastatin calcium
Citations are publications that use Tocris products. Selected citations for Rosuvastatin calcium include:
Rojo-Arreola et al (2014) Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis. PLoS One 9 e87594 PMID: 24489942
Do you know of a great paper that uses Rosuvastatin calcium from Tocris? Please let us know.
Reviews for Rosuvastatin calcium
There are currently no reviews for this product. Be the first to review Rosuvastatin calcium and earn rewards!
Have you used Rosuvastatin calcium?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.